Oban Biopharma
Small biotechnology company focused on discovery of GPCR allosteric therapeutics using computational structural analysis and AI-assisted in silico screening of ultra-large compound libraries. Emphasis is on identification and optimization of positive and negative allosteric modulators to improve receptor selectivity and signaling profiles.
Industries
N/A
Nr. of Employees
small (1-50)
Services
Structure-based mapping of non-orthosteric binding pockets on GPCRs to guide ligand discovery.
Screening workflow that evaluates compounds from very large virtual libraries across multiple computational criteria.
Use of validated AI predictors to assess absorption, distribution, metabolism, excretion and toxicology properties to maximize chemotype potential.
Guidance on medicinal chemistry strategies at validated targets informed by computational analyses.
Structure-based mapping of non-orthosteric binding pockets on GPCRs to guide ligand discovery.
Screening workflow that evaluates compounds from very large virtual libraries across multiple computational criteria.
Use of validated AI predictors to assess absorption, distribution, metabolism, excretion and toxicology properties to maximize chemotype potential.
Guidance on medicinal chemistry strategies at validated targets informed by computational analyses.
Expertise Areas
- GPCR allosteric therapeutics
- Computational structural biology
- AI-assisted drug discovery
- Ultra-large virtual screening
Key Technologies
- Allosteric pocket mapping
- Ultra-large library virtual screening
- AI/ML ADME-Tox prediction
- Computational chemotype analysis
News & Updates
Company founders are listed as inventors or authors on over 100 issued patents or peer-reviewed scientific papers.
Founders previously co-founded biotechnology companies with reported realized value exceeding $13 billion.
Company founders are listed as inventors or authors on over 100 issued patents or peer-reviewed scientific papers.
Founders previously co-founded biotechnology companies with reported realized value exceeding $13 billion.